Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 25, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2b dose-finding clinical study of ARO-ANG3, the company’s
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 19, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 4, 2021 , at 4:30 p.m. EST to discuss its financial results for the fiscal first quarter ended December 31, 2020 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 7, 2020-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 4, 2020 , the Compensation Committee of the Board of Directors approved “inducement” grants to 27 new
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 30, 2020-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Sandler 32 nd Annual Virtual Healthcare Conference – December 1-3, 2020 December 2, 2020 –   Chris Anzalone
View HTML
Toggle Summary Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 25, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the collaboration and license agreement between Arrowhead and Takeda Pharmaceutical Company Limited announced on October 8, 2020 , has now closed.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results
- Conference Call and Webcast Today, November 23 at 4:30 p.m. EST PASADENA, Calif. --(BUSINESS WIRE)--Nov. 23, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2020 . The company is hosting a conference call at 4:30 p.m.
View HTML
Toggle Summary Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020
- ARO-APOC3 achieved triglyceride reductions of 74-92% - ARO-ANG3 achieved triglyceride reductions of 29-75% and LCL-C reductions of 29-35% - Company to host upcoming KOL webinars on ARO-APOC3 and ARO-ANG3 PASADENA, Calif. --(BUSINESS WIRE)--Nov. 13, 2020-- Arrowhead Pharmaceuticals, Inc.
View HTML
Toggle Summary Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease
- Serum Z-AAT reductions of 86-93% - All patients demonstrated greater than 80% reduction in liver Z-AAT monomer - 3 of 4 patients had a decrease in liver globule involvement - 3 of 4 patients demonstrated reductions in Z-AAT polymer with a range of 68-97% - All patients showed ALT reductions
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 9, 2020-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: The Liver Meeting Digital Experience, the Annual Meeting of the American Association for the Study of Liver Disease
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinars on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 4, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on November 18 , and November 19, 2020 , it will host two key opinion leader (KOL) webinars to discuss the company’s two investigational RNA interference (RNAi) based
View HTML